Expert Insights

PV risk stratification models

Read transcript Close transcript

The risk model for survival in P vera discussed by Dr Tefferi is a good start. I think you can fine-tune that, maybe add some molecular data to that risk model. That risk model is, in general, overall survival, but it weighs heavily on age. I think that's one of the shortcomings of that model.

The highest weight in the model is based on age, which I'm not sure that really allows us to tailor a therapy based on that like, you know, it's prognostic but not predictive model. So maybe we need to refine that model to have emphasis on more disease-related features.

Then the other model that will be nice to develop is more comprehensive to predict risk of thrombosis in those patients not just based on age and presence of prior arterial or venous event. You hope that some would be able to incorporate that myeloproliferative feature of the disease in that risk model.

head shot of Dr Komrokji
Rami S Komrokji, MD Clinical Director of the Malignant Hematology Department Moffitt Cancer Center | Tampa, FL
Dr Rami Komrokji is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center and is a professor in medicine and oncologic sciences at the University of South Florida’s College of Medicine. Dr Komrokji has authored or co-authored more than 80 peer-reviewed manuscripts, 20 book chapters, and more than 200 abstracts on hematologic malignancies and is a peer reviewer for such medical journals as Blood, Journal of Clinical Oncology, and Leukemia. Dr Komrokji serves as a member on the MDS Panel of the National Comprehensive Cancer Network® (NCCN®).